UGqirha oyiNtloko kwiSibhedlele soMhlaza kwiYunivesithi yasePeking
UNjingalwazi uZhitao Ying (MD)
●Iingcali: ukuxilongwa kunye nokunyangwa kwe-lymphoma enobungozi, i-immunotherapy yeselula.
●Ilungu leKomiti yeeNgcali eziNcinci ze-Chinese Society of Clinical Oncology (CSCO).
●Ilungu eliselula, iKomiti ye-Hematologic Tumor, i-Chinese Anti-Cancer Association.
●Ilungu leChinese Geriatric Hematology Lymphoma Group.
●Ilungu leKomiti yobuGcisa yoPhando lweKlinikhi yeziyobisi kunye noVavanyo, uMbutho waseTshayina weGeriatric Health Care.
●Ushicilelo lwejenali: ngaphezulu kwamanqaku angama-30 njengombhali wokuqala.
